Oncovara Pharmaceuticals Ltd
Pioneering Breakthroughs in Cancer Treatment
Transforming Oncology, One Innovation at a Time
At Oncovara Pharmaceuticals, we are driven by a single purpose: to revolutionize the way cancer is treated.
Founded in 2025, Oncovara is a next-generation biotech company dedicated to developing precision-targeted therapies that address the most urgent challenges in oncology today.
We combine deep scientific expertise with advanced technologies including AI powered drug discovery, molecular profiling, and biomarker driven development to accelerate the path from lab to life saving treatment.
Our Mission
To deliver safer, smarter, and more effective cancer therapies that improve patient outcomes and extend lives.
What We Do
Innovative Drug Discovery Designing next gen oncology therapeutics targeting hard to treat cancers.
Translational Research bridging science and clinical application through biomarker-informed strategies
.
Pipeline Development Advancing a robust portfolio of preclinical and early stage assets with high impact potential.
Why Oncovara
Science-Driven, Patient-Focused We prioritise patient needs and scientific integrity in everything we do.
Disruptive Technology Leveraging cutting-edge platforms to accelerate development cycles.
Collaborative Vision Building strategic partnerships with academic centers, biotech, and pharma leaders.
Featured Program: OVX-101
Our lead candidate, OVX-101, is a first-in-class inhibitor targeting resistant tumor microenvironments in metastatic solid tumors.
Preclinical results show promising efficacy and safety — with first-in-human trials planned for 2026.
§Copyright © 2025 Oncovara - All Rights Reserved.